August 1, 2023: We asked FDA and those conducting DCTs to recognize how they could inadvertently reduce the enrollment of diverse populations when relying on digital health technologies (DHTs). NCHR then provided strategies and considerations to FDA for implementing decentralized clinical trials, including those that use DHTs.
Read More »On Health Policy
Testimony of Diana Zuckerman at the CMS Meeting Regarding Transitional Coverage for Emerging Technologies
August 1, 2023: Dr. Zuckerman urged CMS to uphold its standard for coverage based on evidence that medical products are proven reasonable and necessary for Medicare patients.
Read More »NCHR Public Comment on HHS Draft Framework to Support and Accelerate Smoking Cessation
July 30, 2023: HHS released a draft framework to support and accelerate smoking cessation. NCHR provided a public comment with recommendations to improve the framework, with a focus on evaluating the impact of demographic differences on the safety and efficacy of different smoking cessation strategies.
Read More »Letter from Experts to CMS and HHS Regarding Data Sharing in Leqembi Registries
July 27, 2023: In a letter to CMS and HHS, policy experts and bioethicists urge CMS to require that registries that make Medicare patients eligible for Leqembi coverage share data with CMS, FDA, and independent researchers to ensure accurate and unbiased data.
Read More »Testimony of Dr. Diana Zuckerman On Bill H.3948
July 26, 2023: We provided written testimony in support of Massachusetts bill H 3948, which would prohibit state and municipal contracts to install artificial turf fields. In October, the bill was reported favorably.
Read More »